CVS Returns Zepbound to Drug Plans After Lilly Slashes Price
Bloomberg.com • • general
Key Points:
- Over 10 million US patients will regain easier insurance access to Eli Lilly’s obesity drug Zepbound after CVS Health reversed restrictions on certain drug plans.
- CVS made the decision following Eli Lilly’s agreement to reduce the price charged to many health plans for Zepbound.
- Earlier in July, CVS Caremark had limited access to Zepbound due to a pricing deal with rival Novo Nordisk for its obesity drug Wegovy.
- The reversal restores coverage for Zepbound, providing more options for patients seeking obesity treatment.